Skip to content
AgilVax Logo
  • Team
  • Products
    • xCT-ADC
    • xCT-mAb
    • AX09-VLP
  • Pipeline
  • Publications
  • Cancer
    • Target
    • Focus
  • News
  • Contact
FocusJordan2020-03-02T20:58:07+00:00
  • Metastatic Breast Cancer

  • Colorectal Cancer

  • Non-small Call Lung Cancer

  • Metastatic Breast Cancer

Metastatic Breast Cancer

There are approximately 3.5 million women living in the US with a history of breast cancer.

Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later in the disease course (distant recurrence), represent the majority of MBC cases and constitute the most advanced form of breast cancer. By 2020 there will be 168,292 women living with MBC in the US.

The majority of the MBC population (3 out of 4) were initially diagnosed with non-metastatic cancer but progress to distant disease. While five-year relative survival is 89.7% for all female breast cancer patients, the rate for MBC patients drops precipitously to 27%. Additionally, 20% of breast cancer deaths in a given year originate from women diagnosed with de novo MBC, whereas 80% are deaths from women diagnosed with earlier stage breast cancer who progressed to recurrent MBC.

  • Colorectal Cancer

Colorectal Cancer

Colorectal Cancer (CRC) is the second leading cause of cancer related deaths in the US for both men and women combined.

Approximately 140,000 new case of colorectal cancer will be diagnosed, and 56,000 people will die from the disease this year.CRC is second only to lung cancer in numbers of deaths in the US. It has been reported that xCT expression is associated with tumor recurrence in patients with CRC. Patients with xCT-positive tumors represent a high-risk group for disease recurrence.
  • Non-small Call Lung Cancer

Non-small Cell Lung Cancer

An estimated 234,000 adults in the US will be diagnosed with lung cancer.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for 80-85% of all lung cancer diagnoses. Lung Cancer is the second most common and the leading cancer death for men and women. It is estimated that 154,000 deaths from this disease will occur each year.

It has also been reported that there is overexpression of xCT in NSCLC and the expression of xCT was correlated with advanced stage and predicted a worse 5-year survival.

footer-logo
Contact Us

Team

xCT-ADC

xCT-mAb

AX09-VLP

Publications

Target

Focus

News

Contact

Copyright © AgilVax 2020. Website Design and Development by Ingenuity Software Labs